Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Osong Public Health Res Perspect > Volume 10(6); 2019 > Article
Original Article
Prevalence and Associated Factors of Hypertension Subtypes Among the Adult Population in Nepal: Evidence from Demographic and Health Survey Data
Rajat Das Guptaa,b,c, Animesh Talukdara,d,e, Shams Shabab Haiderb, Mohammad Rifat Haiderf
Osong Public Health and Research Perspectives 2019;10(6):327-336.
DOI: https://doi.org/10.24171/j.phrp.2019.10.6.02
Published online: December 31, 2019

aCentre for Non-Communicable Diseases and Nutrition, BRAC James P Grant School of Public Health, BRAC University, Mohakhali, Dhaka, Bangladesh

bCentre for Science of Implementation & Scale-Up, BRAC James P Grant School of Public Health, BRAC University, Mohakhali, Dhaka, Bangladesh

cDepartment of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA

dCAPABLE Consortium, University of Cambridge, UK

ePublic Health and Informatics, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

fDepartment of Social and Public Health, College of Health Sciences and Professions, Ohio University, Athens, USA

*Corresponding author: Rajat Das Gupta, BRAC James P Grant School of Public Health, BRAC University, Mohakhali, Dhaka, Bangladesh, E-mail: rajat89.dasgupta@gmail.com
• Received: September 19, 2019   • Revised: November 16, 2019   • Accepted: November 19, 2019

Copyright ©2019, Korea Centers for Disease Control and Prevention

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

  • 7,741 Views
  • 114 Download
  • 6 Crossref
  • 5 Scopus
prev next
This article has been corrected. See "Correction to “Prevalence and Associated Factors of Hypertension Subtypes Among the Adult Population in Nepal: Evidence from Demographic and Health Survey Data” [Osong Public Health Res Perspect 2019;10(6):327–36] " in Volume 13 on page 80.
  • Objectives
    This study aims to determine the prevalence, and associated factors of undiagnosed hypertension [Systolic Diastolic Hypertension (SDH), Isolated Systolic Hypertension (ISH) and Isolated Diastolic Hypertension (IDH)] in the Nepalese adult population.
  • Methods
    Nepal Demographic and Health Survey 2016 data from adults (≥ 18 years) was used in this study. The final weighted sample size was 13,393. Blood pressure (BP) was measured 3 times and the average of the second and third measurement was reported. SDH (systolic BP (SBP) ≥ 140 mmHg and diastolic BP (DBP) ≥ 90 mmHg), ISH (SBP ≥ 140 mmHg and DBP < 90 mmHg), and IDH (SBP < 140 mmHg and DBP ≥ 90 mmHg) were measured. Multilevel logistic regression analyses were conducted to find the association between the independent variables and the covariates.
  • Results
    The prevalence of SDH, IDH and ISH were 8.1%, 7.5%, and 3.3% respectively. The odds of having SDH and ISH increased with old age. However, the odds of having IDH decreased with increasing age. Females has lower odds of having SDH and IDH compared with male participants. Individuals that had been married, resided in Province 4 (p < 0.05) or 5 (p < 0.01) were statistically significantly associated with having IDH. Being overweight or obese was statistically significantly associated with all 3 HTN subtypes (p < 0.001).
  • Conclusion
    The necessary steps should be taken so that public health promotion programs in Nepal may prevent and control undiagnosed hypertension.
Hypertension (HTN) is prevalent worldwide and a major public health problem because of the significant role it plays in the development of cardiovascular and cerebrovascular diseases [1,2]. It is one of the principal modifiable risk factors in both the development of cardiovascular diseases and the resultant morbidity and mortality [3,4]. Globally, about 13% of the total deaths each year is attributable to HTN [5]. In addition, HTN accounts for about 4% of the annual disability-adjusted life-years [6].
The American College of Cardiology and the American Heart Association (2017) defined HTN primarily in 2 stages. Stage 1 is defined as systolic arterial blood pressure [systolic BP (SBP)] between 130–139 mmHg and a diastolic arterial BP (DBP) between 80–89 mmHg. Stage 2 is defined as the systolic arterial blood pressure being 140 mmHg or above, and the diastolic arterial BP being 90 mmHg or above [7]. However, in many hypertensive patients, HTN does not manifest its classical form and SBP or DBP may rise independently. In these cases HTN is known as Isolated Systolic Hypertension [ISH (SBP ≥ 140 mmHg and DBP < 90 mmHg)] and Isolated Diastolic Hypertension [IDH (SBP < 140 mmHg and DBP ≥ 90 mmHg)] [811]. Increased stiffness or reduced elasticity of the arteries causes ISH, whereas IDH is induced by a rise in arteriole resistance [12]. ISH has been reported to be more common among older adults [13], and associated with an increased risk of developing cardiac failure in the elderly [14]. In the past, IDH did not get as much consideration as the other forms of HTN [11,15], but its importance should not be overlooked [16]. IDH also increases the risk of developing cardiovascular diseases, though the magnitude is lower than with other HTN subtypes [10]. Combined systolic/diastolic HTN (SDH) is also associated with cardiovascular and cerebrovascular diseases [17].
Lowering the mean DBP was reportedly associated with a reduced risk of developing cerebrovascular, and coronary heart diseases by 35–40% and 20–25%, respectively [18,19]. Additionally, a meta-analysis of 61 longitudinal studies showed that people aged 40–69 years had an absolute proportional difference in BPs that was almost the same as an absolute proportional difference in mortality risk due to cardiovascular diseases, up to a certain level of DBP and SBP [20]. In that study, an absolute proportional difference of 20 mmHg in SBP or 10 mmHg in DBP was reported to be associated with a 2-fold absolute proportional difference in the mortality risk due to myocardial infarction or cerebrovascular attacks, wherein SBP and DBP were at least 115 mmHg and 75 mmHg, respectively [20].
The World Health Organization (WHO) reported the alarming burden non-communicable diseases (NCDs) pose worldwide and regionally. More than two-thirds of deaths globally, and about three-quarters of deaths in low- and middle-income countries are attributable to NCDs [5]. Like other parts of the world, South Asian countries have undergone overwhelming demographic and epidemiological transitions. Consequently, there has been a massive shift in cause-specific mortality. The burden of NCDs, such as metabolic disease, cardiovascular disease, and cancers has increased and South Asian people have been more susceptible to these diseases, compared to other ethnic groups [2123]. Nepal, is currently facing an epidemiological transition due to the increasing burden of NCDs, including HTN [24]. Data from the nationally representative Nepal Demographic and Health Survey (NDHS) in 2016, estimated that 1 in 5 adults in Nepal (aged ≥ 18 years) were hypertensive [25,26]. However, Nepal does not have representative data regarding HTN subtypes and their associated factors. The burden of NCDs in Nepal, along with ISH and IDH, warrant regular reporting of nationally representative data on HTN subtypes, so that preventive modalities can be designed. This study aims to determine the prevalence, distribution, and associated factors of ISH, IDH as well as SDH, in Nepal using the NDHS 2016 data.
1. Study design
A secondary analysis of the nationally representative Nepal Demographic and Health Survey (NDHS) 2016 data was conducted. Under the leadership of the Nepal Ministry of Health, NDHS 2016 was administered by NEW ERA from June 2016 to January 2017 [25].
NDHS 2016 utilized the updated sampling frame of the 2011 Nepal National Population and Housing Census. For data collection, stratified cluster sampling of households was followed. In the rural area, a 2-staged stratified sampling technique was followed. At first, 199 primary sampling units (PSUs) were selected based on the probability proportional to size method. At the second stage, households were systematically selected from each PSU. On the other hand, a 3-staged stratified sampling technique was used in the urban area. At the first stage, PSUs (n = 184) were selected by the probability proportional to size method. Then, enumeration areas were randomly selected from each PSU. At the final stage, households were systematically selected from each enumeration area. A total of 11,490 households (5,520 urban households and 5,970 rural households) were included in the final sample. The detailed methodology has been previously published [25].
2. Outcome
Adult Nepalese men and women aged 18 years and above were included in this study. The outcomes of interest of this study were ISH, IDH, and combined systolic/diastolic HTN (SDH). BP was measured using UA-767F/FAC (A&D Medical) BP monitors, and depending on the respondent’s arm circumference, small, medium, or large size cuffs were used. For each individual, BP was measured 3 times. After discarding the first measurement, the average of the second and third measurement was reported as the BP of the respondent [25]. In this study, HTN was defined as having an average SBP ≥ 140 mmHg and an average DBP ≥ 90 mmHg. If the individual was taking any antihypertensive medication at the time of the survey irrespective of BP level, he/she was classified as hypertensive [27]. SDH was defined as an average SBP ≥ 140 mmHg and an average DBP ≥ 90 mm Hg [8]. ISH was defined as an average SBP ≥ 140 mmHg and an average DBP < 90 mmHg, and IDH was defined as an average SBP < 140 mmHg and an average DBP ≥ 90 mm Hg [8].
3. Explanatory variables
Based on literature review, potential explanatory variables that were considered included age (18–29 years, 30–49 years, 50–69 years, ≥ 70 years), gender (male, female), marital status (never married, had been married), highest educational attainment (no formal education, primary education, secondary education and above), household wealth index (poorest, poor, middle, rich, richest), place of residence (urban, rural), province of residence (Province 1, Province 2, Province 3, Province 4, Province 5, Province 6, Province 7), ecological region of residence (the Terai, hills, mountains), and body mass index [BMI, underweight (< 18.5 kg/m2), normal weight (18.5–23 kg/m2), overweight/obese (≥ 23 kg/m2)]. BMI was defined using the Asian cut-off value [28]. Household wealth index was calculated using principal component analysis of selected assets, i.e., construction materials used for the roof and floor of the household, types of water source and sanitation facilities, access to electricity, and other belongings (television, bicycle, etc.) [25,29,30].
4. Statistical analysis
Descriptive analyses of the selected variables (both of the outcome variable and the covariates) were conducted. As all the variables were categorical, they were described using frequencies and percentages. Pearson’s Chi-square test was used to observe any differences among the covariates across the BP status of the respondents. The sample weight of the NDHS 2016 was adjusted during the analyses.
Multilevel logistic regression analyses were conducted to find the association between the independent variables (SDH, ISH, and IDH) and the covariates. Multilevel logistic regression was conducted considering the complex hierarchical structure of the DHS dataset [3133]. At first, bivariate analysis was performed to determine the crude odds ratio (COR) with a 95% confidence interval (CI) with each of the covariates. Those variables, which yielded a pre-determined p < 0.2 in the bivariate analyses (which was sufficient to adjust for the additional residual confounding effect), were put into the final multivariate logistic regression model to yield the adjusted odds ratio (AOR) [34]. In the final logistic regression model, those covariates which yielded a p < 0.05 were considered statistically significant. Any possible existence of multicolinearity among the covariates was checked using the variance inflation factor. A variance inflation factor value greater than 5 was considered as an indication of multicolinearity [35]. However, no statistically significant multicolinearity was observed. Stata 14.0 was used for data analyses. The guidelines outlined in the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement were followed in conducting this study and writing the manuscript (Appendix A) [36].
5. Ethical consideration
NDHS, 2016 received ethical approval from the ethical review board of the Nepal Research Council (approval number: 329/2015) and ICF International (approval no.: ICF IRB FWA00002349). Before data collection, informed consent was given by the respondents.
1. Characteristics of the respondents
A weighted sample of 13,393 Nepalese males and females aged ≥ 18 years of age, were included in the final analyses. Nearly two-thirds (61.2%) of the respondents were from urban areas. About two-fifths (41.6%) of the study participants did not have any formal education. The respondents were almost equally distributed across the 5 wealth quintiles. Almost half of the people (49.6%) were from the Terai region, 44% belonged to the hilly areas, and the rest (6.4%) were from the mountains. More than a third (36%) of the participants were overweight or obese (Table 1).
The weighted prevalence of HTN was 21.1%. The group of young adults (18–29 years of age) had the least prevalence of HTN (6.1%) compared to the other age groups. Around one-fifth (21.7%) of the middle-aged (30–49 years), and about two-thirds (34.5%) of the older adults (50–69 years) had HTN. The elderly group (≥ 70 years of age) had the highest proportion (43.5%) of HTN. The prevalence of HTN was higher among males than females (male versus female: 25.4% versus 18%, p < 0.001). The highest prevalence of HTN was observed among those with no formal education (24.5%, p < 0.001), from the richest wealth quintile (28.3%, p < 0.001). Around a quarter of the Nepalese population in Province 3, Province 4, and Province 5, had HTN (24.9%, 28.8%, and 23.3%, respectively). The prevalence of HTN was higher in those 3 provinces than in other regions (p < 0.001). Considering the ecology of the habitat, the population in the hilly areas had the highest prevalence of HTN (24.2%, p < 0.001), compared to populations from other ecological regions. Higher prevalence was also observed among overweight/obese individuals (30.8%, p < 0.001) than other BMI categories (Table 1).
2. Age- and gender-specific prevalence of ISH, IDH and SDH
The age- and gender-specific prevalence of ISH, IDH, and SDH are presented in Table 2. Overall, 18.9% of the respondents had undiagnosed and untreated HTN. The prevalence of undiagnosed and untreated SDH, IDH, and ISH was 8.1% (95% CI: 7.4%–8.9%), 7.5% (95% CI: 6.9%–8.1%), and 3.3% (95% CI: 3.0%–3.7%), respectively. The prevalence was higher among males in all 3 sub-categories. In the case of undiagnosed and untreated SDH and ISH, the prevalence in both genders were higher among the older age-groups. However, in the case of undiagnosed and untreated IDH, the highest prevalence was observed in males and females aged 30–49 years.
3. Factors associated with undiagnosed and untreated HTN
The factors associated with undiagnosed and untreated HTN subtypes are described in Table 3. In the multivariate analyses, several demographic variables (e.g. age, gender), socioeconomic variables (e.g. education, province), and BMI were observed to have a statistically significant association with participants having ISH, IDH, or SDH, when adjusted for the potential confounders.
The odds of having undiagnosed and untreated SDH and ISH, were higher among the older age-groups, whereas for IDH it was younger ages. Gender was also statistically significantly associated with undiagnosed and untreated SDH and IDH. Being female was associated with a significantly reduced odds of having undiagnosed and untreated SDH (AOR 0.6; 95% CI: 0.5–0.7, p < 0.001) and IDH (AOR 0.6; 95% CI: 0.5–0.7, p < 0.001). Household wealth index was statistically significantly associated with undiagnosed and untreated SDH and ISH. A Nepalese adult from a poorer quintile household, had higher odds (AOR 1.3; 95% CI: 1.0–1.6, p < 0.05) of having undiagnosed SDH, compared with a person from the poorest quintile household. In contrast, being a person from the richest quintile household increased the odds of having undiagnosed ISH (AOR 1.8; 95% CI: 1.2–2.8, p < 0.01) compared with a person from the poorest quintile household. Residents of Province 4 had higher odds of having undiagnosed and untreated SDH (AOR 1.5; 95% CI: 1.0–2.2, p < 0.05) and IDH (AOR 1.5; 95% CI: 1.1–2.1, p < 0.05) compared to residents from Province 1. In addition, a resident of Province 5 had higher odds (AOR 1.6; 95% CI: 1.2–2.2, p < 0.01) of having undiagnosed and untreated IDH than a resident of Province 1. Being overweight/obese increased the likelihood of having undiagnosed and untreated SDH, ISH, and IDH. An overweight/obese individual was more likely to have undiagnosed and untreated SDH (AOR 2.2; 95% CI: 1.9–2.6, p < 0.001) and IDH (AOR 2.2; 95% CI: 1.9–2.6, p < 0.001) compared to an individual of normal body weight. In contrast, being underweight reduced the odds of having undiagnosed and untreated SDH (AOR 0.6; 95% CI: 0.5–0.8, p < 0.001) and IDH (AOR 0.6; 95% CI: 0.5–0.8, p < 0.001) statistically significantly compared to an individual with a normal body weight.
To the best of our knowledge, this was the first study from Nepal to identify the prevalence, and factors associated with undiagnosed and untreated ISH, IDH, and SDH among the adult population in Nepal. Around one-fifth of the adult Nepalese population was suffering from undiagnosed and untreated HTN. The prevalence of IDH and SDH were high followed by ISH. In both males and females, the prevalence of SDH and ISH increased with age. On the other hand, IDH was more prevalent in the 30–49 years age group. Age, gender, marital status, household wealth status, province of residence, and BMI was associated with HTN subtypes.
The findings of this study were consistent with the studies conducted on HTN subtypes in other developing nations [8,11,37,38]. The prevalence of ISH was similar to the reported prevalence from neighboring Northern India (male: 5.1%; female: 3.6%) and Bangladesh (male: 3.0%; female: 4.7%) [8,38]. On the other hand, it was lower than the reported prevalence of ISH in China (7.6%) [37]. The reported IDH prevalence (7.5%) in this current study was higher than the reported prevalence from Bangladesh (5.2%) and India (4.5%) [8,11]. The SDH prevalence (8.1%) was also higher than the reported prevalence from Bangladesh (5.2%) [8]. Differences in measurement methods may impair direct comparison between studies. The higher prevalence estimates in China may be attributed to the increased westernization compared with its neighboring counterparts [37]. When comparing between studies it should be noted whether a study is regional or national. There is a paucity of nationwide data in terms of prevalence of undiagnosed IDH in India. Kanpur, being an industrial city has better health-care and diagnostic systems, hence a lower estimate of the prevalence of undiagnosed IDH is observed [11]. The Bangladeshi study included an adult population aged ≥ 35 years, whereas the current study included individuals aged ≥ 18 years [8]. This could explain the higher prevalence of IDH in Nepal than that of Bangladesh and India.
The prevalence of ISH and IDH increased and decreased respectively, with increasing age in this current study. Increasing age was observed to be associated with undiagnosed and untreated ISH and SDH. Age is a non-modifiable risk factor of HTN subtypes [39]. With increasing age, and arterial stiffness increases, resulting in a higher prevalence of elevated BP [40]. Previous evidence showed that between the age of 30–84 years, the prevalence of SBP increases [41]. The prevalence of IDH was the highest among the 30–49 years age group. The odds of IDH decreased with increasing age. This is because diastolic DBP increases up to the age of 50 years due to increased peripheral vascular resistance in small blood vessels, and then gradually decreases [40,41].
Being male was positively associated with SDH and IDH. Aryal et al [42] reported a higher prevalence of smoking, physical inactivity, high blood sugar, and total blood cholesterol among Nepalese males, compared to their female counterparts [42]. Smoking, physical inactivity, high blood sugar, and total blood cholesterol were major risk factors, which increase arterial stiffness and contributed to HTN [4346]. The findings in this current study do not align with a similar study performed in neighboring Bangladesh, where being female was reported to be a major associated factor for HTN subtypes [8].
Like the previous studies on HTN performed in Nepal, this current study did not show any consistent relationship patterns between wealth index and HTN subtypes [47,48]. In this study, only the richest wealth index showed a positive association with SDH. People of the richest households tended to have a higher calorific intake, which was compounded with the increased likelihood of leading a sedentary lifestyle, and developing SDH [49].
Residence in Province 4 (later officially renamed Gandaki Pradesh) was positively associated with ISH and IDH. In addition, residence in Province 5 also showed a positive association with IDH. This provincial difference in the associated factors of HTN has been observed in Nepal [26,50]. Regional variations due to differences in socioeconomic conditions and dietary habits have been previously observed in other countries. For Nepal in particular, such disparities led to substantial regional differences in health status [51,52]. Although the higher odds of undiagnosed and untreated IDH in Province 4 and 5 could be attributed to such regional differences of societal and population characteristics, this was beyond the scope of analysis in this current study. Further studies are needed to understand why the prevalence of ISH and IDH was higher in these provinces.
This current study observed that being overweight or obese was positively associated with all of the HTN subtypes, an association previously reported [8,53]. The BP of obese individuals increases due to sympathetic activation, structural changes in the kidney, impairment of pressure natriuresis, and impairment of the renin-angiotensin system, which are further coupled with a high level of circulating insulin, corticosteroid, leptin, and neuropeptides [54]. HTN prevention, and control programs in Nepal should focus on overweight and obese individuals for targeted high-risk approaches.
This study has several notable strengths. The findings of the study are generalizable to the Nepalese people, as a nationally representative sample was analyzed. Due to the utilization of standard and validated tools, the possibility of measurement error was less than other equivalent studies performed in Nepal. The limitations of this study include the causal relationship between the independent and outcome variables which could not be established due to the cross-sectional nature of the study. BP was measured in a single visit, although the standard guidelines recommended longitudinal measurement [27,52]. The relationship between several HTN subtypes with lifestyle factors (dietary habits and physical activities), and smoking could not be evaluated as the NDHS 2016 did not collect data on those variables.
This study observed a high prevalence of undiagnosed and untreated HTN subtypes in the adult Nepalese population. Given the public health importance of these conditions, necessary steps (including awareness against the known risk factors, promotion of physical activity and healthy diet) should be taken by public health promotion programs in Nepal. People who are older, male, overweight or obese, who have a higher socioeconomic condition and are residents of Province 4 (Gandaki Pradesh) or Province 5, had a higher likelihood of suffering HTN and should be enrolled in HTN prevention and control programs.
Acknowledgements
The authors are thankful to the DHS program for providing permission to use their dataset.

Conflicts of Interest

The authors report no conflicts of interest.

  • 1. Zhou D, Xi B, Zhao M, et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: The NHANES III Linked Mortality Study. Sci Rep 2018;8(1). 9418PMID: 10.1038/s41598-018-27377-2. PMID: 29925884. PMID: 6010458.ArticlePubMedPMCPDF
  • 2. Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int 2010;107(49). 866−73. PMID: 21191547. PMID: 3011179.ArticlePubMedPMC
  • 3. Cooper RS, Amoah AG, Mensah GA. High blood pressure: the foundation for epidemic cardiovascular disease in African populations. Ethn Dis 2003;13(2 Suppl 2). S48−52. PMID: 13677414.PubMed
  • 4. Bridget BK, Fuster V. Promoting cardiovascular health in the developing world: a critical challenge to achieve global health. Washington, DC (WA): National Academies Press; 2010. pp 2560−72.
  • 5. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva (Switzerland): World Health Organization; 2014.
  • 6. World Health Organization. Global Health Observatory (GHO) data. Raised blood pressure: Situation and trends. Geneva (Switzerland): World Health Organization; 2015.
  • 7. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017;70(14). 1785−822. PMID: 10.1016/j.jacc.2017.07.745. PMID: 28886926.ArticlePubMed
  • 8. Ahmed S, Pervin S, Biswas T, et al. Undiagnosed Isolated Systolic and Diastolic Hypertension Subtypes and Their Correlates in Bangladesh: A Nationwide Survey. Osong Public Health Res Perspect 2019;10(1). 12−9. PMID: 10.24171/j.phrp.2019.10.1.04. PMID: 30847266. PMID: 6396825.ArticlePubMedPMCPDF
  • 9. Liu F, Adi D, Xie X, et al. Prevalence of Isolated Diastolic Hypertension and Associated Risk Factors among Different Ethnicity Groups in Xinjiang, China. PLoS One 2015;10(12). e0145325PMID: 10.1371/journal.pone.0145325. PMID: 26694755. PMID: 4690591.ArticlePubMedPMC
  • 10. Arima H, Murakami Y, Lam TH, et al. Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific Region. Hypertension 2012;59(6). 1118−23. PMID: 10.1161/HYPERTENSIONAHA.111.187252. PMID: 22547441.ArticlePubMed
  • 11. Midha T, Lalchandani A, Nath B, et al. Prevalence of isolated diastolic hypertension and associated risk factors among adults in Kanpur, India. Indian Heart J 2012;64(4). 374−9. PMID: 10.1016/j.ihj.2012.06.007. PMID: 22929820. PMID: 3860613.ArticlePubMedPMC
  • 12. Kelly TN, Gu D, Chen J, et al. Hypertension subtype and risk of cardiovascular disease in Chinese adults. Circulation 2008;118(15). 1558−66. PMID: 10.1161/CIRCULATIONAHA.107.723593. PMID: 18809800. PMID: 2735390.ArticlePubMedPMC
  • 13. Tsimploulis A, Sheriff HM, Lam PH, et al. Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. Int J Cardiol 2017;235:11−6. PMID: 10.1016/j.ijcard.2017.02.139. PMID: 28291625. PMID: 6454896.ArticlePubMedPMC
  • 14. Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: A propensity-matched study. Hypertension 2009;53(3). 458−65. PMID: 10.1161/HYPERTENSIONAHA.108.119792. PMID: 19188527. PMID: 2887759.ArticlePubMedPMC
  • 15. Sever P. Abandoning diastole. BMJ 1999;318(7200). 1773PMID: 10.1136/bmj.318.7200.1773. PMID: 10381743. PMID: 1116117.ArticlePubMed
  • 16. Franklin SS, Pio JR, Wong ND, et al. Predictors of new-onset diastolic and systolic hypertension: The Framingham Heart Study. Circulation 2005;111(9). 1121−7. PMID: 10.1161/01.CIR.0000157159.39889.EC. PMID: 15723980.ArticlePubMed
  • 17. Inoue R, Ohkubo T, Kikuya M, et al. Stroke risk in systolic and combined systolic and diastolic hypertension determined using ambulatory blood pressure. The Ohasama study. Am J Hypertens 2007;20(10). 1125−31. PMID: 10.1016/j.amjhyper.2007.04.017. PMID: 17903698.ArticlePubMedPDF
  • 18. Mishra CP, Kumar S. Risk factors of hypertension in a rural area of Varanasi. Indian J Prev Soc Med 2011;42(1). 101−11.
  • 19. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693). 827−38. PMID: 10.1016/0140-6736(90)90944-Z. PMID: 1969567.ArticlePubMed
  • 20. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349). 1903−13. PMID: 10.1016/S0140-6736(02)11911-8. PMID: 12493255.ArticlePubMed
  • 21. Misra A, Tandon N, Ebrahim S, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: Current status and future directions. BMJ 2017;357:j1420PMID: 10.1136/bmj.j1420. PMID: 28400361.ArticlePubMed
  • 22. Siegel KR, Patel SA, Ali MK. Non-communicable diseases in South Asia: Contemporary perspectives. Br Med Bull 2014;111(1). 31−44. PMID: 10.1093/bmb/ldu018. PMID: 25190759. PMID: 4416117.ArticlePubMedPMCPDF
  • 23. Narain JP, Garg R, Fric A. Non-communicable diseases in the South-East Asia region: Burden, strategies and opportunities. Natl Med J India 2011;24(5). 280−7.PubMed
  • 24. Mishra SR, Neupane D, Bhandari PM, et al. Burgeoning burden of non-communicable diseases in Nepal: A scoping review. Global Health 2015;11:32PMID: 10.1186/s12992-015-0119-7. PMID: 26178459. PMID: 4504073.ArticlePubMedPMCPDF
  • 25. Haque M, Hossain S, Ahmed KR, et al. A Comparative Study on Knowledge about Reproductive Health among Urban and Rural Women of Bangladesh. J Family Reprod Health 2015;9(1). 35−40. PMID: 25904966. PMID: 4405515.PubMedPMC
  • 26. Hasan M, Sutradhar I, Akter T, et al. Prevalence and determinants of hypertension among adult population in Nepal: Data from Nepal Demographic and Health Survey 2016. PloS One 2018;13(5). e0198028PMID: 10.1371/journal.pone.0198028. PMID: 29852006. PMID: 5978874.ArticlePubMedPMC
  • 27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289(19). 2560−72. PMID: 10.1001/jama.289.19.2560. PMID: 12748199.ArticlePubMed
  • 28. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403). 157−63. PMID: 10.1016/S0140-6736(03)15268-3. PMID: 14726171.ArticlePubMed
  • 29. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data--or tears: An application to educational enrollments in states of India. Demography 2001;38(1). 115−32. PMID: 11227840.ArticlePubMed
  • 30. Jolliffe IT, Cadima J. Principal component analysis: A review and recent developments. Philos Trans A Math Phys Eng Sci 2016;374(2065). 20150202PMID: 10.1098/rsta.2015.0202. PMID: 26953178. PMID: 4792409.ArticlePubMedPMC
  • 31. Goldstein H. Multilevel statistical models. Bristol (UK): University of Bristol; 2011. pp 1−21.
  • 32. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. College Station (TX): Stata press; 2008.
  • 33. Hox JJ, Moerbeek M, Van de Schoot R. Multilevel analysis: Techniques and applications. Routledge; 2017. PMID: 10.4324/9781315650982.
  • 34. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138(11). 923−36. PMID: 10.1093/oxfordjournals.aje.a116813. PMID: 8256780.ArticlePubMedPDF
  • 35. Kutner M, Nachtsheim C, Neter J. Applied Linear Statistical Models. 4th edition. Irwin (ID): McGraw-Hill; 2004.
  • 36. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann Intern Med 2007;147(8). 573−7. PMID: 10.7326/0003-4819-147-8-200710160-00010. PMID: 17938396.ArticlePubMed
  • 37. Huang J, Wildman RP, Gu D, et al. Prevalence of isolated systolic and isolated diastolic hypertension subtypes in China. Am J Hypertens 2004;17(10). 955−62. PMID: 10.1016/j.amjhyper.2004.06.007. PMID: 15485760.ArticlePubMedPDF
  • 38. Midha T, Idris M, Saran R, et al. Isolated Systolic Hypertension and its Determinants - A Cross-sectional Study in the Adult Population of Lucknow District in North India. Indian J Community Med 2010;35(1). 89−93. PMID: 10.4103/0970-0218.62579. PMID: 20606929. PMID: 2888377.ArticlePubMedPMC
  • 39. Lee S-H, Kim Y-S, Sunwoo S, et al. A retrospective cohort study on obesity and hypertension risk among Korean adults. J Korean Med Sci 2005;20(2). 188−95. PMID: 10.3346/jkms.2005.20.2.188. PMID: 15831985. PMID: 2808590.ArticlePubMedPMC
  • 40. Pinto E. Blood pressure and ageing. Postgrad Med J 2007;83(976). 109−14. PMID: 10.1136/pgmj.2006.048371. PMID: 17308214. PMID: 2805932.ArticlePubMedPMC
  • 41. Franklin SS. Ageing and hypertension: The assessment of blood pressure indices in predicting coronary heart disease. J Hypertens Suppl 1999;17(5). S29−36.
  • 42. Aryal KK, Mehata S, Neupane S, et al. The Burden and Determinants of Non Communicable Diseases Risk Factors in Nepal: Findings from a Nationwide STEPS Survey. PLoS One 2015;10(8). e0134834PMID: 10.1371/journal.pone.0134834. PMID: 26244512. PMID: 4526223.ArticlePubMedPMC
  • 43. Doonan RJ, Hausvater A, Scallan C, et al. The effect of smoking on arterial stiffness. Hypertens Res 2010;33(5). 398−410. PMID: 10.1038/hr.2010.25. PMID: 20379189.ArticlePubMedPDF
  • 44. Ahmadi-Abhari S, Sabia S, et al. Physical Activity, Sedentary Behavior, and Long-Term Changes in Aortic Stiffness: The Whitehall II Study. J Am Heart Assoc 2017;6(8). e005974PMID: 10.1161/JAHA.117.005974. PMID: 28784651. PMID: 5586440.ArticlePubMedPMC
  • 45. Chen Y, Huang Y, Li X, et al. Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension. Endocrine 2009;36(2). 262−7. PMID: 10.1007/s12020-009-9221-z. PMID: 19598004.ArticlePubMedPDF
  • 46. Wilkinson I, Cockcroft JR. Cholesterol, lipids and arterial stiffness. Adv Cardiol 2007;44:261−77. PMID: 10.1159/000096747.ArticlePubMed
  • 47. Khan RJ, Stewart CP, Christian P, et al. A cross-sectional study of the prevalence and risk factors for hypertension in rural Nepali women. BMC Public Health 2013;13:55PMID: 10.1186/1471-2458-13-55. PMID: 23336578. PMID: 3566953.ArticlePubMedPMCPDF
  • 48. Dhungana RR, Pandey AR, Bista B, et al. Prevalence and Associated Factors of Hypertension: A Community-Based Cross-Sectional Study in Municipalities of Kathmandu, Nepal. Int J Hypertens 2016;2016:1656938. PMID: 10.1155/2016/1656938. PMID: 27293880. PMID: 4880705.ArticlePDF
  • 49. Reddy KS, Naik N, Prabhakaran D. Hypertension in the developing world: A consequence of progress. Curr Cardiol Rep 2006;8(6). 399−404. PMID: 10.1007/s11886-006-0096-9. PMID: 17059790.ArticlePubMedPDF
  • 50. Kibria GMA, Swasey K, Sharmeen A, et al. Prevalence and associated factors of pre-hypertension and hypertension in Nepal: Analysis of the Nepal Demographic and Health Survey 2016. Health Sci Rep 2018;1(10). e83PMID: 10.1002/hsr2.83.ArticlePubMedPMC
  • 51. Johnson DC, Lhaki P, Cherry CB, et al. Spatial analysis of the regional variation of reproductive tract infections and spousal migration correlates in Nepal. Geospat Health 2017;12(1). 513PMID: 10.4081/gh.2017.513. PMID: 28555484.ArticlePubMed
  • 52. Goli S, Bhandari P, Atla UM, et al. Childhood mortality differentials by ecological region in Nepal. Popul Space Place 2017;23(2). e1977PMID: 10.1002/psp.1977.Article
  • 53. Kotsis V, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res 2010;33(5). 386−93. PMID: 10.1038/hr.2010.9. PMID: 20442753.ArticlePubMedPDF
  • 54. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Soc Hypertens 2018;71:e13−e115.
Table 1
Demographic characteristics of the respondents according to blood pressure status (n = 13,393).
Characteristics Overall Hypertensive blood pressure status p


N = 13,393 No (N = 10,566)+ Yes (N = 2,827)+



n % n % n %
Age (y) < 0.001
 18–29 4,337 32.4 4,071 93.9 266 6.1
 30–49 5,002 37.4 3,918 78.3 1,083 21.7
 50–69 3,188 23.8 2,087 65.5 1,101 34.5
 ≥ 70 866 6.5 489 56.5 377 43.5

Gender < 0.001
 Male 5,620 42.0 4,191 74.6 1429 25.4
 Female 7,773 58.0 6,375 82.0 1398 18.0

Marital status < 0.001
 Never married 1,529 11.4 1,426 93.3 103 6.7
 Have been married 11,864 88.6 9,140 77.0 2724 23.0

Education < 0.001
 No formal education 5,572 41.6 4,207 75.5 1365 24.5
 Primary 2,172 16.2 1,698 78.2 474 21.8
 Secondary 3,699 27.6 3,019 81.6 680 18.4
 Higher 1,950 14.6 1,641 84.2 309 15.8

Household wealth status < 0.001
 Poorest 2,396 17.9 1,947 81.3 449 18.7
 Poorer 2,594 19.4 2,046 78.9 549 21.1
 Middle 2,666 19.9 2,191 82.2 475 17.8
 Richer 2,917 21.8 2,363 81.0 554 19.0
 Richest 2,820 21.1 2,019 71.6 801 28.4

Place of residence 0.0147
 Urban 8,191 61.2 6,360 77.6 1,831 22.4
 Rural 5,201 38.8 4,206 80.9 996 19.1

Province < 0.001
 Province 1 2,365 17.7 1,889 79.9 475 20.1
 Province 2 2,748 20.5 2,308 84.0 440 16.0
 Province 3 2,933 21.9 2,202 75.1 732 24.9
 Province 4 1,380 10.3 982 71.2 398 28.8
 Province 5 2,184 16.3 1,675 76.7 509 23.3
 Province 6 674 5.0 565 83.9 109 16.1
 Province 7 1,109 8.3 945 85.2 164 14.8

Ecological region < 0.001
 Mountains 856 6.4 701 81.9 155 18.1
 Hills 5,895 44.0 4,469 75.8 1426 24.2
 The Terai 6,642 49.6 5,395 81.2 1,246 18.8

Body mass index < 0.001
 Normal weight 6,342 47.4 5,310 83.7 1,031 16.3
 Underweight 2,224 16.6 1,914 86.0 311 14.0
 Overweight/obese 4,826 36.0 3,342 69.2 1,485 30.8

+ = row percentage.

Table 2
Age and gender specific prevalence of ISH- IDH- and combined systolic/diastolic hypertension in the adult Nepalese population.
Age (y) Total hypertension (n) Diagnosed and treated hypertension (%), 95% CI Undiagnosed & untreated hypertension

SDH (%), 95% CI ISH (%), 95% CI IDH (%), 95% CI
2,827 2.2 (1.9–2.6) 8.1 (7.4–8.9) 3.3 (3.0–3.7) 7.5 (6.9–8.1)

Male
 Age (y)
 18–29 143 0.7 (0.4–1.3) 1.7 (1.1–2.5) 5.3 (0.3–1.1) 6.0 (4.7–7.7)
 30–49 557 1.5 (0.8–2.7) 11.7 (10.0–13.7) 1.0 (0.6–1.7) 13.2 (11.5–15.0)
 50–69 540 4.2 (3.1–5.6) 17.0 (14.7–19.6) 6.8 (5.1–9.0) 7.3 (6.0–8.9)
 ≥ 70 189 7.4 (4.8–11.1) 13.2 (10.1–17.1) 18.5 (14.6–23.3) 3.0 (1.7–5.2)

Total 1,429 2.5 (1.9–3.2) 10.4 (9.3–11.6) 3.9 (3.2–4.6) 8.7 (7.9–9.6)

Female
 Age (y)
 18–29 122 0.2 (0.0–0.4) 0.8 (0.4–1.4) 0.1 (0.1–0.3) 3.5 (2.7–4.4)
 30–49 527 1.5 (1.0–2.2) 5.5 (4.6–6.5) 1.0 (0.6–1.6) 9.7 (8.5–11.1)
 50–69 561 5.0 (4.0–6.4) 14.9 (12.9–17.2) 7.1 (5.9–8.6) 6.8 (5.5–8.3)
 ≥ 70 188 6.1 (4.0–9.3) 16.2 (12.5–20.7) 19.7 (16.0–24.0) 3.1 (1.8–5.2)

Total 1,398 2.1 (1.7–2.5) 6.4 (5.8–7.2) 3.0 (2.5–3.5) 6.6 (5.9–7.3)

CI = confidence interval; SDH = systolic diastolic hypertension; ISH = isolated systolic hypertension; IDH = isolated diastolic hypertension.

Table 3
Unadjusted and adjusted odds ratios for factors associated with hypertension amongst adults in Nepal.
Characteristics Undiagnosed & untreated SDH Undiagnosed & untreated ISH Undiagnosed & untreated IDH



COR (95% CI) AOR (95% CI) COR (95% CI) AOR (95% CI) COR (95% CI) AOR (95% CI)
Age (y)
 18–29 Ref Ref Ref Ref Ref Ref
 30–49 9.1*** (6.7–12.3) 7.2*** (5.1–10.2) 4.6*** (2.4–8.8) 4.6*** (2.2–9.6) 3.1*** (2.6–3.6) 2.4*** (1.9–2.9)
 50–69 22.3*** (16.5–30.3) 19.7*** (13.7–28.2) 39.6*** (21.5–73.0) 42.9*** (20.9–88.1) 2.5*** (2.1–3.1) 2.3*** (1.8–3.0)
 ≥ 70 28.5*** (20.0–40.6) 29.4*** (19.4–44.6) 144.6*** (77.0–271.4) 166.5*** (78.7–352.4) 1.41 (1.0–2.2) 1.6* (1.0–2.5)

Gender
 Male Ref Ref Ref Ref Ref Ref
 Female 0.5*** (0.5–0.6) 0.6*** (0.5–0.7) 0.7*** (0.6–0.8) 0.9 (0.7–1.2) 0.6*** (0.6–0.7) 0.6*** (0.5–0.7)

Marital status
 Never married Ref Ref Ref Ref Ref Ref
 Have been married 6.2*** (4.2–9.2) 1.0 (0.6–1.6) 6.4*** (3.4–12.1) 0.6 (0.3–1.3) 2.8*** (2.1–3.8) 1.5* (1.1–2.1)

Education
 No formal education Ref Ref Ref Ref Ref Ref
 Primary 0.7*** (0.6–0.8) 0.9 (0.8–1.2) 0.4*** (0.3–0.6) 1.1 (0.7–1.5) 1.3* (1.0–1.5) 1.1 (0.9–1.4)
 Secondary 0.5*** (0.4–0.5) 1.0 (0.8–1.2) 0.2*** (0.1–0.3) 0.9 (0.6–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.4)
 Higher 0.3*** (0.3–0.4) 0.9 (0.6–1.2) 0.1*** (0.1–0.2) 0.8 (0.4–1.4) 0.9 (0.8–1.2) 1.1 (0.9–1.5)

Household wealth status
 Poorest Ref Ref Ref Ref Ref Ref
 Poorer 1.21 (1.0–1.5) 1.3* (1.0–1.6) 1.0 (0.7–1.3) 1.1 (0.8–1.5) 1.1 (0.9–1.4) 1.1 (0.8–1.4)
 Middle 1.0 (0.8–1.3) 1.1 (0.9–1.5) 0.8 (0.6–1.1) 0.9 (0.6–1.4) 1.0 (0.8–1.3) 1.0 (0.8–1.3)
 Richer 1.1 (0.8–1.3) 1.1 (0.8–1.4) 0.9 (0.7–1.3) 1.1 (0.8–1.6) 1.21 (1.0–1.5) 1.1 (0.8–1.4)
 Richest 1.4*** (1.1–1.9) 1.2 (0.9–1.7) 1.31 (0.9–1.7) 1.8** (1.2–2.8) 1.6*** (1.3–2.0) 1.1 (0.8–1.5)

Place of residence
 Urban Ref Not included in the final model Ref (0.7–1.1) Not included in the final model 0.8* Ref Ref
 Rural 0.9 (0.7–1.1) 0.9 (0.7–1.0) 0.9 (0.8–1.1)

Province
 Province 1 Ref Ref Ref Ref Ref Ref
 Province 2 0.7* (0.5–1.0) 0.8 (0.6–1.2) 0.8 (0.6–1.2) 0.9 (0.6–1.5) 1.0 (0.7–1.3) 1.2 (0.9–1.8)
 Province 3 1.31 (0.9–1.8) 1.1 (0.7–1.6) 1.0 (0.7–1.4) 0.8 (0.5–1.2) 1.7** (1.2–2.2) 1.4 (1.0–1.9)
 Province 4 1.8*** (1.3–2.5) 1.5* (1.0–2.2) 1.41 (1.0–2.1) 1.4 (0.9–2.2) 1.8*** (1.3–2.4) 1.5* (1.1–2.1)
 Province 5 1.2 (0.9–1.7) 1.3 (0.9–1.9) 1.3 (0.9–1.8) 1.5 (1.0–2.2) 1.5* (1.1–2.0) 1.6** (1.2–2.2)
 Province 6 0.7* (0.5–0.9) 0.8 (0.5–1.2) 0.6* (0.4–1.0) 0.8 (0.5–1.4) 1.31 (0.9–1.7) 1.3 (0.9–1.9)
 Province 7 0.6** (0.4–0.8) 0.7 (0.5–1.0) 0.71 (0.5–1.1) 0.8 (0.5–1.2) 0.9 (0.6–1.2) 1.1 (0.8–1.5)

Ecological region
 Mountains Ref Ref Ref Ref Ref Ref
 Hills 1.8** (1.2–2.7) 1.4 (0.9–2.2) 1.51 (0.9–2.3) 1.2 (0.7–2.1) 1.4* (1.0–2.0) 1.2 (0.8–1.7)
 The Terai 1.2 (0.8–1.8) 1.1 (0.7–1.7) 1.3 (0.8–2.1) 1.1 (0.6–2.0) 1.0 (0.7–1.5) 0.9 (0.6–1.4)

Body mass index
 Normal weight Ref Ref Ref Ref Ref Ref
 Underweight 0.8* (0.6–1.0) 0.6*** (0.5–0.8) 1.5** (1.2–2.0) 0.9 (0.7–1.2) 0.6*** (0.4–0.7) 0.6*** (0.5–0.8)
 Overweight/obese 2.2*** (1.9–2.6) 2.2*** (1.9–2.6) 1.5** (1.2–1.8) 1.6*** (1.2–2.1) 2.5*** (2.2–2.9) 2.2*** (1.9–2.6)

1 p < 0.2,

* p < 0.05,

** p < 0.01,

*** p < 0.001.

Variable with p < 0.2 from unadjusted model were included into multivariate analysis STROBE 2007 (v4) Statement-Checklist of items that should be included in reports of cross-sectional studies.

ANC = antenatal care; AOR = adjusted odds ratio; CI = confidence interval; COR = crude odds ratio; ACC/AHA = American College of Cardiology/American Heart Association; SDH = systolic diastolic hypertension; ISH = isolated systolic hypertension; IDH = isolated diastolic hypertension.

Appendix A
Prevalence and associated factors of hypertension subtypes among the adult population in Nepal: Evidence from the Demographic and Health Survey data.
Section/Topic Item# Recommendation Reported on page #
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2–3

Introduction

Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 4–6
Objectives 3 State specific objectives, including any prespecified hypotheses 6

Methods

Study design 4 Present key elements of study design early in the paper 6–7
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection 6–7
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants 6–7
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable 7–8
Data sources/measurement 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group 7–8
Bias 9 Describe any efforts to address potential sources of bias 8–9
Study size 10 Explain how the study size was arrived at 8–9
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why 6–9
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 8–9
(b) Describe any methods used to examine subgroups and interactions 8–9
(c) Explain how missing data were addressed Not applicable
(d) If applicable, describe analytical methods taking account of sampling strategy 8–9
(e) Describe any sensitivity analyses Not applicable

Results

Participants 13* (a) Report numbers of individuals at each stage of study e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed 9–10
(b) Give reasons for non-participation at each stage Not applicable
(c) Consider use of a flow diagram Not applicable
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders 9–10
(b) Indicate number of participants with missing data for each variable of interest Not applicable
Outcome data 15* Report numbers of outcome events or summary measures 9–12
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included 9–12
(b) Report category boundaries when continuous variables were categorized 9–12
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable
Other analyses 17 Report other analyses performed e.g. analyses of subgroups and interactions, and sensitivity analyses Not applicable

Discussion

Key results 18 Summarize key results with reference to study objectives 12
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 14–15
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 12–15
Generalizability 21 Discuss the generalizability (external validity) of the study results 14–15
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 15

* Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Hypertension subtypes at high altitude in Peru: Analysis of the Demographic and Family Health Survey 2016–2019
      Brando Ortiz-Saavedra, Elizbet S. Montes-Madariaga, Oscar Moreno-Loaiza, Carlos J. Toro-Huamanchumo, Esteban Ortiz-Prado
      PLOS ONE.2024; 19(4): e0300457.     CrossRef
    • Structural And Functional State Of Various Zones Of Skin Microcirculation In Men With Isolated Diastolic Hypertension
      Andrei I. Korolev, Andrei A. Fedorovich, Aleksander Yu. Gorshkov, Valida A. Dadaeva, Mikhail G. Chaschin, Anna V. Strelkova, Ksenia V. Omelyanenko, Maria A. Mikhailova, Oxana M. Drapkina
      Russian Open Medical Journal.2024;[Epub]     CrossRef
    • Isolated diastolic hypertension and cardiovascular outcomes across different diagnostic guidelines: a systematic review and meta-analysis
      Abhimanyu Agarwal, Mohamed A. Mostafa, Muhammad Imtiaz Ahmad, Elsayed Z. Soliman
      The Egyptian Heart Journal.2024;[Epub]     CrossRef
    • Correction to “Prevalence and Associated Factors of Hypertension Subtypes Among the Adult Population in Nepal: Evidence from Demographic and Health Survey Data” [Osong Public Health Res Perspect 2019;10(6):327–36]
      Rajat Das Gupta, Animesh Talukder, Shams Shabab Haider, Mohammad Rifat Haider
      Osong Public Health and Research Perspectives.2022; 13(1): 80.     CrossRef
    • Is Isolated Diastolic Hypertension an Important Phenotype?
      Cesar A. Romero, Aldo H. Tabares, Marcelo Orias
      Current Cardiology Reports.2021;[Epub]     CrossRef
    • Relationship between cigarette smoking and blood pressure in adults in Nepal: A population-based cross-sectional study
      Renqiao Lan, Max K. Bulsara, Prakash Dev Pant, Hilary Jane Wallace, Palash Chandra Banik
      PLOS Global Public Health.2021; 1(11): e0000045.     CrossRef

    Related articles
    Prevalence and Associated Factors of Hypertension Subtypes Among the Adult Population in Nepal: Evidence from Demographic and Health Survey Data
    Prevalence and Associated Factors of Hypertension Subtypes Among the Adult Population in Nepal: Evidence from Demographic and Health Survey Data
    Characteristics Overall Hypertensive blood pressure status p


    N = 13,393 No (N = 10,566)+ Yes (N = 2,827)+



    n % n % n %
    Age (y) < 0.001
     18–29 4,337 32.4 4,071 93.9 266 6.1
     30–49 5,002 37.4 3,918 78.3 1,083 21.7
     50–69 3,188 23.8 2,087 65.5 1,101 34.5
     ≥ 70 866 6.5 489 56.5 377 43.5

    Gender < 0.001
     Male 5,620 42.0 4,191 74.6 1429 25.4
     Female 7,773 58.0 6,375 82.0 1398 18.0

    Marital status < 0.001
     Never married 1,529 11.4 1,426 93.3 103 6.7
     Have been married 11,864 88.6 9,140 77.0 2724 23.0

    Education < 0.001
     No formal education 5,572 41.6 4,207 75.5 1365 24.5
     Primary 2,172 16.2 1,698 78.2 474 21.8
     Secondary 3,699 27.6 3,019 81.6 680 18.4
     Higher 1,950 14.6 1,641 84.2 309 15.8

    Household wealth status < 0.001
     Poorest 2,396 17.9 1,947 81.3 449 18.7
     Poorer 2,594 19.4 2,046 78.9 549 21.1
     Middle 2,666 19.9 2,191 82.2 475 17.8
     Richer 2,917 21.8 2,363 81.0 554 19.0
     Richest 2,820 21.1 2,019 71.6 801 28.4

    Place of residence 0.0147
     Urban 8,191 61.2 6,360 77.6 1,831 22.4
     Rural 5,201 38.8 4,206 80.9 996 19.1

    Province < 0.001
     Province 1 2,365 17.7 1,889 79.9 475 20.1
     Province 2 2,748 20.5 2,308 84.0 440 16.0
     Province 3 2,933 21.9 2,202 75.1 732 24.9
     Province 4 1,380 10.3 982 71.2 398 28.8
     Province 5 2,184 16.3 1,675 76.7 509 23.3
     Province 6 674 5.0 565 83.9 109 16.1
     Province 7 1,109 8.3 945 85.2 164 14.8

    Ecological region < 0.001
     Mountains 856 6.4 701 81.9 155 18.1
     Hills 5,895 44.0 4,469 75.8 1426 24.2
     The Terai 6,642 49.6 5,395 81.2 1,246 18.8

    Body mass index < 0.001
     Normal weight 6,342 47.4 5,310 83.7 1,031 16.3
     Underweight 2,224 16.6 1,914 86.0 311 14.0
     Overweight/obese 4,826 36.0 3,342 69.2 1,485 30.8
    Age (y) Total hypertension (n) Diagnosed and treated hypertension (%), 95% CI Undiagnosed & untreated hypertension

    SDH (%), 95% CI ISH (%), 95% CI IDH (%), 95% CI
    2,827 2.2 (1.9–2.6) 8.1 (7.4–8.9) 3.3 (3.0–3.7) 7.5 (6.9–8.1)

    Male
     Age (y)
     18–29 143 0.7 (0.4–1.3) 1.7 (1.1–2.5) 5.3 (0.3–1.1) 6.0 (4.7–7.7)
     30–49 557 1.5 (0.8–2.7) 11.7 (10.0–13.7) 1.0 (0.6–1.7) 13.2 (11.5–15.0)
     50–69 540 4.2 (3.1–5.6) 17.0 (14.7–19.6) 6.8 (5.1–9.0) 7.3 (6.0–8.9)
     ≥ 70 189 7.4 (4.8–11.1) 13.2 (10.1–17.1) 18.5 (14.6–23.3) 3.0 (1.7–5.2)

    Total 1,429 2.5 (1.9–3.2) 10.4 (9.3–11.6) 3.9 (3.2–4.6) 8.7 (7.9–9.6)

    Female
     Age (y)
     18–29 122 0.2 (0.0–0.4) 0.8 (0.4–1.4) 0.1 (0.1–0.3) 3.5 (2.7–4.4)
     30–49 527 1.5 (1.0–2.2) 5.5 (4.6–6.5) 1.0 (0.6–1.6) 9.7 (8.5–11.1)
     50–69 561 5.0 (4.0–6.4) 14.9 (12.9–17.2) 7.1 (5.9–8.6) 6.8 (5.5–8.3)
     ≥ 70 188 6.1 (4.0–9.3) 16.2 (12.5–20.7) 19.7 (16.0–24.0) 3.1 (1.8–5.2)

    Total 1,398 2.1 (1.7–2.5) 6.4 (5.8–7.2) 3.0 (2.5–3.5) 6.6 (5.9–7.3)
    Characteristics Undiagnosed & untreated SDH Undiagnosed & untreated ISH Undiagnosed & untreated IDH



    COR (95% CI) AOR (95% CI) COR (95% CI) AOR (95% CI) COR (95% CI) AOR (95% CI)
    Age (y)
     18–29 Ref Ref Ref Ref Ref Ref
     30–49 9.1*** (6.7–12.3) 7.2*** (5.1–10.2) 4.6*** (2.4–8.8) 4.6*** (2.2–9.6) 3.1*** (2.6–3.6) 2.4*** (1.9–2.9)
     50–69 22.3*** (16.5–30.3) 19.7*** (13.7–28.2) 39.6*** (21.5–73.0) 42.9*** (20.9–88.1) 2.5*** (2.1–3.1) 2.3*** (1.8–3.0)
     ≥ 70 28.5*** (20.0–40.6) 29.4*** (19.4–44.6) 144.6*** (77.0–271.4) 166.5*** (78.7–352.4) 1.41 (1.0–2.2) 1.6* (1.0–2.5)

    Gender
     Male Ref Ref Ref Ref Ref Ref
     Female 0.5*** (0.5–0.6) 0.6*** (0.5–0.7) 0.7*** (0.6–0.8) 0.9 (0.7–1.2) 0.6*** (0.6–0.7) 0.6*** (0.5–0.7)

    Marital status
     Never married Ref Ref Ref Ref Ref Ref
     Have been married 6.2*** (4.2–9.2) 1.0 (0.6–1.6) 6.4*** (3.4–12.1) 0.6 (0.3–1.3) 2.8*** (2.1–3.8) 1.5* (1.1–2.1)

    Education
     No formal education Ref Ref Ref Ref Ref Ref
     Primary 0.7*** (0.6–0.8) 0.9 (0.8–1.2) 0.4*** (0.3–0.6) 1.1 (0.7–1.5) 1.3* (1.0–1.5) 1.1 (0.9–1.4)
     Secondary 0.5*** (0.4–0.5) 1.0 (0.8–1.2) 0.2*** (0.1–0.3) 0.9 (0.6–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.4)
     Higher 0.3*** (0.3–0.4) 0.9 (0.6–1.2) 0.1*** (0.1–0.2) 0.8 (0.4–1.4) 0.9 (0.8–1.2) 1.1 (0.9–1.5)

    Household wealth status
     Poorest Ref Ref Ref Ref Ref Ref
     Poorer 1.21 (1.0–1.5) 1.3* (1.0–1.6) 1.0 (0.7–1.3) 1.1 (0.8–1.5) 1.1 (0.9–1.4) 1.1 (0.8–1.4)
     Middle 1.0 (0.8–1.3) 1.1 (0.9–1.5) 0.8 (0.6–1.1) 0.9 (0.6–1.4) 1.0 (0.8–1.3) 1.0 (0.8–1.3)
     Richer 1.1 (0.8–1.3) 1.1 (0.8–1.4) 0.9 (0.7–1.3) 1.1 (0.8–1.6) 1.21 (1.0–1.5) 1.1 (0.8–1.4)
     Richest 1.4*** (1.1–1.9) 1.2 (0.9–1.7) 1.31 (0.9–1.7) 1.8** (1.2–2.8) 1.6*** (1.3–2.0) 1.1 (0.8–1.5)

    Place of residence
     Urban Ref Not included in the final model Ref (0.7–1.1) Not included in the final model 0.8* Ref Ref
     Rural 0.9 (0.7–1.1) 0.9 (0.7–1.0) 0.9 (0.8–1.1)

    Province
     Province 1 Ref Ref Ref Ref Ref Ref
     Province 2 0.7* (0.5–1.0) 0.8 (0.6–1.2) 0.8 (0.6–1.2) 0.9 (0.6–1.5) 1.0 (0.7–1.3) 1.2 (0.9–1.8)
     Province 3 1.31 (0.9–1.8) 1.1 (0.7–1.6) 1.0 (0.7–1.4) 0.8 (0.5–1.2) 1.7** (1.2–2.2) 1.4 (1.0–1.9)
     Province 4 1.8*** (1.3–2.5) 1.5* (1.0–2.2) 1.41 (1.0–2.1) 1.4 (0.9–2.2) 1.8*** (1.3–2.4) 1.5* (1.1–2.1)
     Province 5 1.2 (0.9–1.7) 1.3 (0.9–1.9) 1.3 (0.9–1.8) 1.5 (1.0–2.2) 1.5* (1.1–2.0) 1.6** (1.2–2.2)
     Province 6 0.7* (0.5–0.9) 0.8 (0.5–1.2) 0.6* (0.4–1.0) 0.8 (0.5–1.4) 1.31 (0.9–1.7) 1.3 (0.9–1.9)
     Province 7 0.6** (0.4–0.8) 0.7 (0.5–1.0) 0.71 (0.5–1.1) 0.8 (0.5–1.2) 0.9 (0.6–1.2) 1.1 (0.8–1.5)

    Ecological region
     Mountains Ref Ref Ref Ref Ref Ref
     Hills 1.8** (1.2–2.7) 1.4 (0.9–2.2) 1.51 (0.9–2.3) 1.2 (0.7–2.1) 1.4* (1.0–2.0) 1.2 (0.8–1.7)
     The Terai 1.2 (0.8–1.8) 1.1 (0.7–1.7) 1.3 (0.8–2.1) 1.1 (0.6–2.0) 1.0 (0.7–1.5) 0.9 (0.6–1.4)

    Body mass index
     Normal weight Ref Ref Ref Ref Ref Ref
     Underweight 0.8* (0.6–1.0) 0.6*** (0.5–0.8) 1.5** (1.2–2.0) 0.9 (0.7–1.2) 0.6*** (0.4–0.7) 0.6*** (0.5–0.8)
     Overweight/obese 2.2*** (1.9–2.6) 2.2*** (1.9–2.6) 1.5** (1.2–1.8) 1.6*** (1.2–2.1) 2.5*** (2.2–2.9) 2.2*** (1.9–2.6)
    Section/Topic Item# Recommendation Reported on page #
    Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1
    (b) Provide in the abstract an informative and balanced summary of what was done and what was found 2–3

    Introduction

    Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 4–6
    Objectives 3 State specific objectives, including any prespecified hypotheses 6

    Methods

    Study design 4 Present key elements of study design early in the paper 6–7
    Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection 6–7
    Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants 6–7
    Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable 7–8
    Data sources/measurement 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group 7–8
    Bias 9 Describe any efforts to address potential sources of bias 8–9
    Study size 10 Explain how the study size was arrived at 8–9
    Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why 6–9
    Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 8–9
    (b) Describe any methods used to examine subgroups and interactions 8–9
    (c) Explain how missing data were addressed Not applicable
    (d) If applicable, describe analytical methods taking account of sampling strategy 8–9
    (e) Describe any sensitivity analyses Not applicable

    Results

    Participants 13* (a) Report numbers of individuals at each stage of study e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed 9–10
    (b) Give reasons for non-participation at each stage Not applicable
    (c) Consider use of a flow diagram Not applicable
    Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders 9–10
    (b) Indicate number of participants with missing data for each variable of interest Not applicable
    Outcome data 15* Report numbers of outcome events or summary measures 9–12
    Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included 9–12
    (b) Report category boundaries when continuous variables were categorized 9–12
    (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable
    Other analyses 17 Report other analyses performed e.g. analyses of subgroups and interactions, and sensitivity analyses Not applicable

    Discussion

    Key results 18 Summarize key results with reference to study objectives 12
    Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 14–15
    Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 12–15
    Generalizability 21 Discuss the generalizability (external validity) of the study results 14–15
    Other information
    Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 15
    Table 1 Demographic characteristics of the respondents according to blood pressure status (n = 13,393).

    = row percentage.

    Table 2 Age and gender specific prevalence of ISH- IDH- and combined systolic/diastolic hypertension in the adult Nepalese population.

    CI = confidence interval; SDH = systolic diastolic hypertension; ISH = isolated systolic hypertension; IDH = isolated diastolic hypertension.

    Table 3 Unadjusted and adjusted odds ratios for factors associated with hypertension amongst adults in Nepal.

    p < 0.2,

    p < 0.05,

    p < 0.01,

    p < 0.001.

    Variable with p < 0.2 from unadjusted model were included into multivariate analysis STROBE 2007 (v4) Statement-Checklist of items that should be included in reports of cross-sectional studies.

    ANC = antenatal care; AOR = adjusted odds ratio; CI = confidence interval; COR = crude odds ratio; ACC/AHA = American College of Cardiology/American Heart Association; SDH = systolic diastolic hypertension; ISH = isolated systolic hypertension; IDH = isolated diastolic hypertension.

    Appendix A Prevalence and associated factors of hypertension subtypes among the adult population in Nepal: Evidence from the Demographic and Health Survey data.

    Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

    Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.


    PHRP : Osong Public Health and Research Perspectives
    TOP